Chiron Licenses Acute Rejection Agent From Novartis

novartis has acquired exclusive worldwide development and commercialization rights to aerosolized cyclosporine (AcsA), an agent with potential in lung transplant acute rejection from .

Clinical studies have been conducted in about 100 lung transplant patients at the University of Pittsburgh.

Terms of agreement were not disclosed. Corporation, headquartered in Emeryville, California, has a strategic focus on cancer and infectious disease and commercializes its products through three business units: biopharmaceuticals, vaccines and blood testing.

Online Steroids

Dragon Pharma is specialized in the manufacturing of generic steroid gear Trenbolone 200 On-Line.